Roche Holding : Après une baisse en 2020, le BPA devrait marquer une pause en 2021
>Pas de croissance en vue en CHF en 2021 - Dans un contexte difficile (biosimilaires, coronavirus), Roche a rempli son objectif 2020 en publiant hier une croissance de son BPA de 4% à changes constants. Mais force est de constater que l’effet change puissant (-9% sur le BPA) a conduit la société à publier un BPA Core en recul de 5%. Si la société reconduit logiquement ses ambitions pour 2021 (croissance des ventes et du BPA low to mid single digit à changes constants)...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.